Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.
Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.
Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.
Current State of Evaluation and Management of Infectious Conditions in Liver Transplant Candidates and Recipients
Submission Deadline: February 10, 2018 (Open) Submit Now
Wasim A. Dar, MD, PhD
About This Topic
Liver transplantation is a critical therapy for the effective management of patients suffering from the complications of end stage liver disease. Outcomes from liver transplantation are vastly improved from the days of its early practice due to increasing technical proficiency during the surgery itself. However this has brought to light other important factors that influence survival including the morbidity and mortality from pre- and post-transplant infectious conditions. Evaluation and management of these infectious conditions therefore will continue to play a larger role in both selecting appropriate transplant candidates and management of patients after receiving a liver transplant. In this special issue of OBM Transplantation we are soliciting scholarly articles devoted to reviewing the current paradigms of care related to such topics as HIV and liver transplantation, the management of Hepatitis B and C pre- and post-transplant, viral reactivation diseases after liver transplantation, and fungal and bacterial diseases and their management affecting liver transplant recipients.
Title: HIV in Liver Transplantation
Title: Viral Reactivation Diseases in Liver Transplantation
Title: Bacterial Infections in Liver Transplantation
Title: HCV in Liver Transplantation